DIA 2022 Global Annual Meeting

Component Type: Forum
Level: Intermediate

The popular panel is back this year to report out on a 4-year analysis conducted on over 5,000 clinical trials. We looked at the study-level and surveyed how risk-based and quality-by-design approaches are being adopted across the industry. The panel will report out on our landscape data findings, discuss the implications for clinical trial operations, and lay out the trends that indicate how industry is adopting risk-based strategies. We will take questions from the audience and engage in a discussion about how to implement these risk-based and quality-by-design strategies, and why you should.

Learning Objectives

Describe how risk-based approaches are being used in the industry, and how adoption shifted during the COVID pandemic and afterwards; Identify components that are being underutilized (e.g., centralized monitoring) and discuss potential benefits of adopting them; Explain how your organization can benefit from taking a risk-based quality management approach to every study.

Chair

Anina Adelfio

Speaker

An Industry Clinical Trialist Executive Becomes the Diagnosed Patient Volunteer: What has been Learned Thus Far?
Peter A. DiBiaso, MHA